Search Results - "Shepherd, Pat"

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia by MILOJKOVIC, Dragana, NICHOLSON, Emma, KHORASHAD, Jamshid S, DE LAVALLADE, Hugues, REZVANI, Katy, PALIOMPEIS, Christos, GOLDMAN, John M, MARIN, David, APPERLEY, Jane F, HOLYOAKE, Tessa L, SHEPHERD, Pat, DRUMMOND, Mark W, SZYDIO, Richard, BUA, Marco, FORONI, Letizia, REID, Alistair

“…Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximately 50% of patients with chronic myeloid leukemia in chronic phase in…”
Get full text

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed by IBRAHIM, Amr R, CLARK, Richard E, HOLYOAKE, Tessa L, BYRNE, Jenny, SHEPHERD, Pat, APPERLEY, Jane F, MILOJKOVIC, Dragana, SZYDLO, Richard, GOLDMAN, John, MARIN, David

“…It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid…”
Get full text

Treatment of CML using IFN-alpha: impact on quality of life by Homewood, Janis, Watson, Maggie, Richards, Sue M, Halsey, Jim, Shepherd, Pat C A

“…Treatment of chronic myeloid leukaemia (CML) with IFN-alpha (IFN) is known to confer significant survival benefit, but the drug's impact on quality of life…”
Get more information

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study by Gallipoli, Paolo, Shepherd, Pat, Irvine, David, Drummond, Mark, Holyoake, Tessa

Get full text

Panhypopituitarism secondary to a macroprolactinoma manifesting with pancytopenia: case report and literature review by Holmes, George I, Shepherd, Pat, Walker, James D

“…To present a case of pancytopenia associated with hypopituitarism secondary to a macroprolactinoma. We report the clinical features on presentation and results…”
Get more information

Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia by Heaney, Nicholas B., Copland, Mhairi, Stewart, Karen, Godden, Judith, Parker, Anne N., McQuaker, I. Grant, Smith, Graeme M., Crawley, Charles, Shepherd, Pat, Holyoake, Tessa L.

“…Patients with newly diagnosed chronic phase chronic myeloid leukemia were treated with imatinib mesylate (IM) for 6 to 12 months to establish disease control,…”
Get full text

Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia by Heaney, Nicholas, Copland, Mhairi, Stewart, Karen, Godden, Judith, Parker, Anne, McQuaker, Grant, Smith, Graeme, Crawley, Charles, Shepherd, Pat, Holyoake, Tessa L.

“…Recommended first-line therapy for patients with chronic phase (CP) CML is imatinib mesylate (IM). Although IM induces complete cytogenetic responses (CCR) in…”
Get full text

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib by Heaney, Nicholas, Drummond, Mark, Kaeda, Jaspal, Nicolini, Franck, Clark, Richard, Wilson, George, Shepherd, Pat, Tighe, Jane, McLintock, Lorna, Hughes, Timothy, Holyoake, Tessa L.

“…Imatinib mesylate (IM) induces complete cytogenetic responses (CCR) in the majority of patients with CML in chronic phase (CP). Despite this reduction in…”
Get full text

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa by Marin, David, Marktel, Sarah, Szydlo, Richard, Klein, John P, Bua, Marco, Foot, Nicola, Olavarria, Eduardo, Shepherd, Pat, Kanfer, Edward, Goldman, John M, Apperley, Jane F

“…Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We…”
Get full text

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha by Hasford, J, Pfirrmann, M, Shepherd, P, Guilhot, J, Hehlmann, R, Mahon, FX, Kluin-Nelemans, HC, Ohnishi, K, Steegmann, JL, Thaler, J

“…Universite Victor Segalen, Bordeaux, France; University Hospital Groningen, Groningen, The Netherlands. has@ibe.med.uni-muenchen.de BACKGROUND AND OBJECTIVES:…”
Get full text

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon by HASFORD, Joerg, PFIRRMANN, Markus, SHEPHERD, Pat, GUILHOT, Joëlle, HEHLMANN, Rudiger, MAHON, Francois-Xavier, KLUIN-NELEMANS, Hanneke C, OHNISHI, Kazunori, STEEGMANN, Juan Luis, THALER, Josef

Get full text

Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia by Shepherd, P, Dhanapala, C, Maguire, C, White, J, Drummond, M, Holyoake, T, Johnson, P R E

“…Imatinib is a tyrosine kinase inhibitor, which selectively antagonises the BCR-ABL molecular pathway which causes chronic myeloid leukaemia (CML). Imatinib was…”
Get more information

Not so NICE for CML by Goldman, John, Apperley, Jane, Clark, Richard, Green, Tony, Holyoake, Tessa, O'Brien, Stephen, Shepherd, Pat

Get full text

Readers to the Rescue: Online Shopping by Shepherd, Pat

Get full text

Readers to the Rescue: Online Investment by Shepherd, Pat

Get full text